Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vitamin D3 or its active form 1α,25(oh) 2 d 3 Application in inhibiting the expression of PD-1

A technology of PD-1 and vitamins, applied in the field of biomedicine, can solve the problems of not finding screening methods, affecting the effect of PD-1 antibodies, and large toxic and side effects, and achieve good tolerance, enhanced function, and no toxic and side effects.

Active Publication Date: 2021-07-27
北京德衍科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Repeated use of PD-1 antibody will produce anti-antibody, which will seriously affect the effect of PD-1 antibody
However, the research and development of small molecule inhibitors of PD-1 is less, the main reason is that no effective screening method has been found so far, and in addition, the potential toxic side effects of artificially synthesized compounds on the body are also relatively large

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vitamin D3 or its active form 1α,25(oh) <sub>2</sub> d <sub>3</sub> Application in inhibiting the expression of PD-1
  • Vitamin D3 or its active form 1α,25(oh) <sub>2</sub> d <sub>3</sub> Application in inhibiting the expression of PD-1
  • Vitamin D3 or its active form 1α,25(oh) <sub>2</sub> d <sub>3</sub> Application in inhibiting the expression of PD-1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] 1α,25(OH) 2 D. 3 (Calcitriol) has the following structural formula:

[0051]

[0052] The above compounds are used as PD-1 inhibitors. This compound is commercially available from Sigma Corporation.

Embodiment 2

[0053] Example 2: Expansion of Vγ9Vδ2 T cells

[0054] The normal human blood buffy coat was separated from the Guangzhou Blood Bank Center. The separation solution (ficoll) was purchased from GE Healthcare, and the gradient centrifugation (600g, 30min, centrifugation conditions: up to 6 down to 2), and the obtained peripheral blood mononuclear cells were selected Sexual expansion culture (culture conditions: on the 0th day, Zol phosphoric acid (Zol, purchased from Sigma Company) 30-50 (μM), the concentration used in this implementation is 40 (μM), recombinant human interleukin 2 (IL-2), 40ng / mL, 1α,25(OH) 2 D. 3 The addition amount is 50 (nmol / L); on the third day, the culture medium is changed without adding Zol, and the recombinant human interleukin 2 is changed to 10ng / mL, 1α,25(OH) 2 D. 3 The amount added was 50 (nmol / L); the ratio of Vγ9Vδ2 / CD3 was detected by flow cytometry on the 12th day. The result is as figure 1 As shown, the results showed that Vγ9Vδ2 T cells ...

Embodiment 3

[0055] Example 3: Protein lysis (RIPA) was performed on the Vγ9Vδ2T cells in Example 2, and 20ug was used for protein gel electrophoresis to detect the protein level of PD-1, and actin was used as an internal reference. The result is as figure 2 As shown, the results show that 1α,25(OH) 2 D. 3 It has a good inhibitory effect on PD-1 of Vγ9Vδ2T cells.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses vitamin D3 or its active form 1α, 25(OH) 2 D. 3 Application in inhibiting the expression of PD‑1. 1α,25(OH) 2 D. 3 VDR can inhibit the expression of PD-1 on the surface of activated CD8 T cells and γδ T cells. At the same time, VDR can also promote the expression of Blimp1. Blimp1 can effectively inhibit the expression of PD-1, thereby enhancing the tumor killing function of T cells. 1α,25(OH) 2 D. 3 It can also be used in combination with cytokines such as IL-2 and IL-15, which can more effectively reduce the expression of immune cell PD-1, and at the same time promote the expression of CD28, thereby enhancing the killing function and metabolic function of T cells and maintaining the immune function of T cells. Steady state, and because vitamin D3 has minimal toxic side effects and a wide tolerance range, it can promote T cells to secrete type I interferon. Therefore, it can be used in the treatment of various diseases, including tumors and infectious diseases.

Description

technical field [0001] The invention belongs to the field of tumor immune cell therapy and antiviral biomedical technology, in particular to vitamin D3 or its active form 1α,25(OH) 2 D. 3 Application in inhibiting PD-1 expression. Background technique [0002] Tumor is one of the major diseases that threaten human health and life at present. Tumor-based treatments mainly include surgical therapy, chemotherapy, radiotherapy and immunotherapy. At present, immunotherapy is in full swing and occupies a large market share. In the process of tumor immunotherapy, currently the world's major pharmaceutical companies mainly use PD-1 monoclonal antibody, among which, the precious Opdivo (El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I..Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/593A61K38/20A61P35/00A61P31/12A61P37/04
Inventor 高云飞尹芝南黎鹏郑良焰
Owner 北京德衍科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com